1887

Abstract

In the 15 years since the discovery of hepatitis C virus (HCV), much has been learned about its role as a major causative agent of human liver disease and its ability to persist in the face of host-cell defences and the immune system. This review describes what is known about the diversity of HCV, the current classification of HCV genotypes within the family and how this genetic diversity contributes to its pathogenesis. On one hand, diversification of HCV has been constrained by its intimate adaptation to its host. Despite the >30 % nucleotide sequence divergence between genotypes, HCV variants nevertheless remain remarkably similar in their transmission dynamics, persistence and disease development. Nowhere is this more evident than in the evolutionary conservation of numerous evasion methods to counteract the cell's innate antiviral defence pathways; this series of highly complex virus–host interactions may represent key components in establishing its ‘ecological niche’ in the human liver. On the other hand, the mutability and large population size of HCV enables it to respond very rapidly to new selection pressures, manifested by immune-driven changes in T- and B-cell epitopes that are encountered on transmission between individuals with different antigen-recognition repertoires. If human immunodeficiency virus type 1 is a precedent, future therapies that target virus protease or polymerase enzymes may also select very rapidly for antiviral-resistant mutants. These contrasting aspects of conservatism and adaptability provide a fascinating paradigm in which to explore the complex selection pressures that underlie the evolution of HCV and other persistent viruses.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80401-0
2004-11-01
2019-12-11
Loading full text...

Full text loading...

/deliver/fulltext/jgv/85/11/vir853173.html?itemId=/content/journal/jgv/10.1099/vir.0.80401-0&mimeType=html&fmt=ahah

References

  1. Adinolfi, L. E., Gambardella, M., Andreana, A., Tripodi, M.-F., Utili, R. & Ruggiero, G. ( 2001; ). Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33, 1358–1364.[CrossRef]
    [Google Scholar]
  2. Bartenschlager, R., Kaul, A. & Sparacio, S. ( 2003; ). Replication of the hepatitis C virus in cell culture. Antiviral Res 60, 91–102.[CrossRef]
    [Google Scholar]
  3. Blight, K. J., Kolykhalov, A. A. & Rice, C. M. ( 2000; ). Efficient initiation of HCV RNA replication in cell culture. Science 290, 1972–1974.[CrossRef]
    [Google Scholar]
  4. Blight, K. J., McKeating, J. A., Marcotrigiano, J. & Rice, C. M. ( 2003; ). Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 77, 3181–3190.[CrossRef]
    [Google Scholar]
  5. Booth, J. C., Kumar, U., Webster, D., Monjardino, J. & Thomas, H. C. ( 1998; ). Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology 27, 223–227.[CrossRef]
    [Google Scholar]
  6. Bukh, J., Purcell, R. H. & Miller, R. H. ( 1993; ). At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. Proc Natl Acad Sci U S A 90, 8234–8238.[CrossRef]
    [Google Scholar]
  7. Bukh, J., Pietschmann, T., Lohmann, V. & 7 other authors ( 2002; ). Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc Natl Acad Sci U S A 99, 14416–14421.[CrossRef]
    [Google Scholar]
  8. Candotti, D., Temple, J., Sarkodie, F. & Allain, J.-P. ( 2003; ). Frequent recovery and broad genotype 2 diversity characterize hepatitis C virus infection in Ghana, west Africa. J Virol 77, 7914–7923.[CrossRef]
    [Google Scholar]
  9. Cantaloube, J.-F., Biagini, P., Attoui, H., Gallian, P., de Micco, P. & De Lamballerie, X. ( 2003; ). Evolution of hepatitis C virus in blood donors and their respective recipients. J Gen Virol 84, 441–446.[CrossRef]
    [Google Scholar]
  10. Chang, K.-M., Rehermann, B., McHutchison, J. G., Pasquinelli, C., Southwood, S., Sette, A. & Chisari, F. V. ( 1997; ). Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 100, 2376–2385.[CrossRef]
    [Google Scholar]
  11. Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W. & Houghton, M. ( 1989; ). Isolation of a cDNA derived from a blood-borne non-A, non-B hepatitis genome. Science 244, 359–362.[CrossRef]
    [Google Scholar]
  12. Clemens, M. J. & Elia, A. ( 1997; ). The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res 17, 503–524.[CrossRef]
    [Google Scholar]
  13. Cochrane, A., Searle, B., Hardie, A. & 7 other authors ( 2002; ). A genetic analysis of hepatitis C virus transmission between injection drug users. J Infect Dis 186, 1212–1221.[CrossRef]
    [Google Scholar]
  14. Colina, R., Casane, D., Vasquez, S., García-Aguirre, L., Chunga, A., Romero, H., Khan, B. & Cristina, J. ( 2004; ). Evidence of intratypic recombination in natural populations of hepatitis C virus. J Gen Virol 85, 31–37.[CrossRef]
    [Google Scholar]
  15. Cooper, S., Erickson, A. L., Adams, E. J., Kansopon, J., Weiner, A. J., Chien, D. Y., Houghton, M., Parham, P. & Walker, C. M. ( 1999; ). Analysis of a successful immune response against hepatitis C virus. Immunity 10, 439–449.[CrossRef]
    [Google Scholar]
  16. De Francesco, R., Tomei, L., Altamura, S., Summa, V. & Migliaccio, G. ( 2003; ). Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res 58, 1–16.[CrossRef]
    [Google Scholar]
  17. de Lamballerie, X., Charrel, R. N., Attoui, H. & De Micco, P. ( 1997; ). Classification of hepatitis C virus variants in six major types based on analysis of the envelope 1 and nonstructural 5B genome regions and complete polyprotein sequences. J Gen Virol 78, 45–51.
    [Google Scholar]
  18. Di Bisceglie, A. M. ( 1997; ). Hepatitis C and hepatocellular carcinoma. Hepatology 26, 34S–38S.[CrossRef]
    [Google Scholar]
  19. Domingo, E., Escarmis, C., Sevilla, N., Moya, A., Elena, S. F., Quer, J., Novella, I. S. & Holland, J. J. ( 1996; ). Basic concepts in RNA virus evolution. FASEB J 10, 859–864.
    [Google Scholar]
  20. Dou, X.-G., Talekar, G., Chang, J., Dai, X., Li, L., Bonafonte, M. T., Holloway, B., Fields, H. A. & Khudyakov, Y. E. ( 2002; ). Antigenic heterogeneity of the hepatitis C virus NS5A protein. J Clin Microbiol 40, 61–67.[CrossRef]
    [Google Scholar]
  21. Drake, J. W., Charlesworth, B., Charlesworth, D. & Crow, J. F. ( 1998; ). Rates of spontaneous mutation. Genetics 148, 1667–1686.
    [Google Scholar]
  22. Enomoto, N., Sakuma, I., Asahina, Y., Kurosaki, M., Murakami, T., Yamamoto, C., Izumi, N., Marumo, F. & Sato, C. ( 1995; ). Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitutions in the NS5a region. J Clin Invest 96, 224–230.[CrossRef]
    [Google Scholar]
  23. Erickson, A. L., Kimura, Y., Igarashi, S. & 7 other authors ( 2001; ). The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15, 883–895.[CrossRef]
    [Google Scholar]
  24. Farci, P., Alter, H. J., Govindarajan, S. & 8 other authors ( 1992; ). Lack of protective immunity against reinfection with hepatitis C virus. Science 258, 135–140.[CrossRef]
    [Google Scholar]
  25. Farci, P., Shimoda, A., Coiana, A. & 9 other authors ( 2000; ). The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288, 339–344.[CrossRef]
    [Google Scholar]
  26. Foy, E., Li, K., Wang, C., Sumpter, R., Jr, Ikeda, M., Lemon, S. M. & Gale, M., Jr ( 2003; ). Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300, 1145–1148.[CrossRef]
    [Google Scholar]
  27. Franchini, M., Rossetti, G., Tagliaferri, A. & 7 other authors ( 2001; ). The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders. Blood 98, 1836–1841.[CrossRef]
    [Google Scholar]
  28. Frank, C., Mohamed, M. K., Strickland, G. T. & 8 other authors ( 2000; ). The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355, 887–891.[CrossRef]
    [Google Scholar]
  29. Frese, M., Pietschmann, T., Moradpour, D., Haller, O. & Bartenschlager, R. ( 2001; ). Interferon-α inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J Gen Virol 82, 723–733.
    [Google Scholar]
  30. Fretz, C., Jeannel, D., Stuyver, L., Hervé, V., Lunel, F., Boudifa, A., Mathiot, C., de Thé, G. & Fournel, J. J. ( 1995; ). HCV infection in a rural population of the Central African Republic (CAR): evidence for three additional subtypes of genotype 4. J Med Virol 47, 435–437.[CrossRef]
    [Google Scholar]
  31. Gale, M. J., Jr, Korth, M. J., Tang, N. M., Tan, S.-L., Hopkins, D. A., Dever, T. E., Polyak, S. J., Gretch, D. R. & Katze, M. G. ( 1997; ). Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230, 217–227.[CrossRef]
    [Google Scholar]
  32. Gao, F., Yue, L., White, A. T. & 7 other authors ( 1992; ). Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. Nature 358, 495–499.[CrossRef]
    [Google Scholar]
  33. Gao, F., Bailes, E., Robertson, D. L. & 9 other authors ( 1999; ). Origins of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397, 436–441.[CrossRef]
    [Google Scholar]
  34. Gates, A. T., Sarisky, R. T. & Gu, B. ( 2004; ). Sequence requirements for the development of a chimeric HCV replicon system. Virus Res 100, 213–222.[CrossRef]
    [Google Scholar]
  35. Girardin, S. E., Sansonetti, P. J. & Philpott, D. J. ( 2002; ). Intracellular vs extracellular recognition of pathogens – common concepts in mammals and flies. Trends Microbiol 10, 193–199.[CrossRef]
    [Google Scholar]
  36. Gitlin, L. & Andino, R. ( 2003; ). Nucleic acid-based immune system: the antiviral potential of mammalian RNA silencing. J Virol 77, 7159–7165.[CrossRef]
    [Google Scholar]
  37. Gong, G., Waris, G., Tanveer, R. & Siddiqui, A. ( 2001; ). Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-κB. Proc Natl Acad Sci U S A 98, 9599–9604.[CrossRef]
    [Google Scholar]
  38. González-Pérez, M. A., Norder, H., Bergström, Å., Lopéz, E., Visoná, K. A. & Magnius, L. O. ( 1997; ). High prevalence of GB virus C strains genetically related to strains with Asian origin in Nicaraguan hemophiliacs. J Med Virol 52, 149–155.[CrossRef]
    [Google Scholar]
  39. Harvala, H., Kalimo, H., Dahllund, L., Santti, J., Hughes, P., Hyypiä, T. & Stanway, G. ( 2002; ). Mapping of tissue tropism determinants in coxsackievirus genomes. J Gen Virol 83, 1697–1706.
    [Google Scholar]
  40. Heinz, F. X., Collett, M. S., Purcell, R. H., Gould, E. A., Howard, C. R., Houghton, M., Moorman, R. J. M., Rice, C. M. & Thiel, H.-J. ( 2000; ). Flaviviridae. In Seventh Report of the International Committee on Taxonomy of Viruses, pp. 859–878. Edited by M. H. V. van Regenmortel, C. M. Fauquet, D. H. L. Bishop, E. B. Carstens, M. K. Estes, S. M. Lemon, J. Maniloff, M. A. Mayo, D. J. McGeoch, C. R. Pringle & R. B. Wickner. San Diego, CA: Academic Press.
  41. Holland-Staley, C. A., Kovari, L. C., Golenberg, E. M., Pobursky, K. J. & Mayers, D. L. ( 2002; ). Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus. Arch Virol 147, 1385–1406.[CrossRef]
    [Google Scholar]
  42. Hoofnagle, J. H. ( 2002; ). Course and outcome of hepatitis C. Hepatology 36, S21–S29.
    [Google Scholar]
  43. Ikeda, M., Yi, M., Li, K. & Lemon, S. M. ( 2002; ). Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol 76, 2997–3006.[CrossRef]
    [Google Scholar]
  44. Jarvis, L. M., Watson, H. G., McOmish, F., Peutherer, J. F., Ludlam, C. A. & Simmonds, P. ( 1994; ). Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J Infect Dis 170, 1018–1022.[CrossRef]
    [Google Scholar]
  45. Jeannel, D., Fretz, C., Traore, Y. & 9 other authors ( 1998; ). Evidence for high genetic diversity and long-term endemicity of hepatitis C virus genotypes 1 and 2 in West Africa. J Med Virol 55, 92–97.[CrossRef]
    [Google Scholar]
  46. Kalinina, O., Norder, H., Mukomolov, S. & Magnius, L. O. ( 2002; ). A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol 76, 4034–4043.[CrossRef]
    [Google Scholar]
  47. Kalinina, O., Norder, H. & Magnius, L. O. ( 2004; ). Full-length open reading frame of a recombinant hepatitis C virus strain from St Petersburg: proposed mechanism for its formation. J Gen Virol 85, 1853–1857.[CrossRef]
    [Google Scholar]
  48. Kantzanou, M., Lucas, M., Barnes, E., Komatsu, H., Dusheiko, G., Ward, S., Harcourt, G. & Klenerman, P. ( 2003; ). Viral escape and T cell exhaustion in hepatitis C virus infection analysed using class I peptide tetramers. Immunol Lett 85, 165–171.[CrossRef]
    [Google Scholar]
  49. Kao, J. H., Chen, P. J., Lai, M. Y. & Chen, D. S. ( 1993; ). Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis. Gastroenterology 105, 583–587.
    [Google Scholar]
  50. Kato, T., Date, T., Miyamoto, M., Furusaka, A., Tokushige, K., Mizokami, M. & Wakita, T. ( 2003; ). Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125, 1808–1817.[CrossRef]
    [Google Scholar]
  51. Kelleher, A. D., Long, C., Holmes, E. C. & 15 other authors ( 2001; ). Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 193, 375–386.[CrossRef]
    [Google Scholar]
  52. Kimura, M. ( 1968; ). Genetic variability maintained in a finite population due to mutational production of neutral and nearly neutral isoalleles. Genet Res 11, 247–269.[CrossRef]
    [Google Scholar]
  53. Kimura, M. ( 1983; ). The Neutral Theory of Molecular Evolution. Cambridge: Cambridge University Press.
  54. King, J. L. & Jukes, T. H. ( 1969; ). Non-Darwinian evolution. Science 164, 788–798.[CrossRef]
    [Google Scholar]
  55. Kumar, U., Brown, J., Monjardino, J. & Thomas, H. C. ( 1993; ). Sequence variation in the large envelope glycoprotein (E2/NS1) of hepatitis C virus during chronic infection. J Infect Dis 167, 726–730.[CrossRef]
    [Google Scholar]
  56. Kuo, G., Choo, Q. L., Alter, H. J. & 17 other authors ( 1989; ). An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244, 362–364.[CrossRef]
    [Google Scholar]
  57. Lai, M. E., Mazzoleni, A. P., Balestriesi, A., Argiolu, F., De Virgilis, S., Cao, A., Purcell, R. H. & Farci, P. ( 1994; ). Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 343, 388–390.[CrossRef]
    [Google Scholar]
  58. Lamarre, D., Anderson, P. C., Bailey, M. & 25 other authors ( 2003; ). An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186–189.[CrossRef]
    [Google Scholar]
  59. Lanford, R. E., Guerra, B., Lee, H., Averett, D. R., Pfeiffer, B., Chavez, D., Notvall, L. & Bigger, C. ( 2003; ). Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(I)-poly(C), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol 77, 1092–1104.[CrossRef]
    [Google Scholar]
  60. Lechner, F., Wong, D. K. H., Dunbar, P. R. & 7 other authors ( 2000; ). Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191, 1499–1512.[CrossRef]
    [Google Scholar]
  61. Lee, A. Y., Polakos, N. K., Otten, G. R., Ulmer, J. B., Houghton, M. & Paliard, X. ( 2000; ). Quantification of the number of cytotoxic T cells specific for an immunodominant HCV-specific CTL epitope primed by DNA immunization. Vaccine 18, 1962–1968.[CrossRef]
    [Google Scholar]
  62. Leslie, A. J., Pfafferott, K. J., Chetty, P. & 26 other authors ( 2004; ). HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10, 282–289.[CrossRef]
    [Google Scholar]
  63. Lohmann, V., Körner, F., Koch, J.-O., Herian, U., Theilmann, L. & Bartenschlager, R. ( 1999; ). Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110–113.[CrossRef]
    [Google Scholar]
  64. Lu, L., Pilot-Matias, T. J., Stewart, K. D. & 7 other authors ( 2004; ). Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother 48, 2260–2266.[CrossRef]
    [Google Scholar]
  65. Macdonald, A. & Harris, M. ( 2004; ). Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 85, 2485–2502.[CrossRef]
    [Google Scholar]
  66. Majumder, M., Ghosh, A. K., Steele, R., Ray, R. & Ray, R. B. ( 2001; ). Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 75, 1401–1407.[CrossRef]
    [Google Scholar]
  67. Makuwa, M., Souquière, S., Telfer, P. & 7 other authors ( 2003; ). Occurrence of hepatitis viruses in wild-born non-human primates: a 3 year (1998-2001) epidemiological survey in Gabon. J Med Primatol 32, 307–314.[CrossRef]
    [Google Scholar]
  68. Mazzeo, C., Azzaroli, F., Giovanelli, S. & 9 other authors ( 2003; ). Ten year incidence of HCV infection in northern Italy and frequency of spontaneous viral clearance. Gut 52, 1030–1034.[CrossRef]
    [Google Scholar]
  69. Mellor, J., Holmes, E. C., Jarvis, L. M., Yap, P. L., Simmonds, P. & The International HCV Collaborative Study Group ( 1995; ). Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. J Gen Virol 76, 2493–2507.[CrossRef]
    [Google Scholar]
  70. Menéndez, C., Sánchez-Tapias, J.-M., Alonso, P.-L. & 8 other authors ( 1999; ). Molecular evidence of mother-to-infant transmission of hepatitis G virus among women without known risk factors for parenteral infections. J Clin Microbiol 37, 2333–2336.
    [Google Scholar]
  71. Mizokami, M., Gojobori, T., Ohba, K., Ikeo, K., Ge, X.-M., Ohno, T., Orito, E. & Lau, J. Y. N. ( 1996; ). Hepatitis C virus types 7, 8 and 9 should be classified as type 6 subtypes. J Hepatol 24, 622–624.[CrossRef]
    [Google Scholar]
  72. Mortimer, P. P. ( 1995; ). Arsphenamine jaundice and the recognition of instrument-borne virus infection. Genitourin Med 71, 109–119.
    [Google Scholar]
  73. Murakami, T., Enomoto, N., Kurosaki, M., Izumi, N., Marumo, F. & Sato, C. ( 1999; ). Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection. Hepatology 30, 1045–1053.
    [Google Scholar]
  74. Ndjomou, J., Pybus, O. G. & Matz, B. ( 2003; ). Phylogenetic analysis of hepatitis C virus isolates indicates a unique pattern of endemic infection in Cameroon. J Gen Virol 84, 2333–2341.[CrossRef]
    [Google Scholar]
  75. Neumann, A. U., Lam, N. P., Dahari, H., Gretch, D. R., Wiley, T. E., Layden, T. J. & Perelson, A. S. ( 1998; ). Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282, 103–107.[CrossRef]
    [Google Scholar]
  76. Nousbaum, J.-B., Polyak, S. J., Ray, S. C., Sullivan, D. G., Larson, A. M., Carithers, R. L., Jr & Gretch, D. R. ( 2000; ). Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol 74, 9028–9038.[CrossRef]
    [Google Scholar]
  77. Okamoto, H., Kojima, M., Okada, S. & 7 other authors ( 1992; ). Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 190, 894–899.[CrossRef]
    [Google Scholar]
  78. Pause, A., Kukolj, G., Bailey, M. & 11 other authors ( 2003; ). An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA. J Biol Chem 278, 20374–20380.[CrossRef]
    [Google Scholar]
  79. Pavesi, A. ( 2001; ). Origin and evolution of GBV-C/hepatitis G virus and relationships with ancient human migrations. J Mol Evol 53, 104–113.[CrossRef]
    [Google Scholar]
  80. Pavio, N., Taylor, D. R. & Lai, M. M. C. ( 2002; ). Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR. J Virol 76, 1265–1272.[CrossRef]
    [Google Scholar]
  81. Pawlotsky, J.-M. ( 2003a; ). Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res 59, 1–11.[CrossRef]
    [Google Scholar]
  82. Pawlotsky, J.-M. ( 2003b; ). The nature of interferon-α resistance in hepatitis C virus infection. Curr Opin Infect Dis 16, 587–592.[CrossRef]
    [Google Scholar]
  83. Pestova, T. V., Shatsky, I. N., Fletcher, S. P., Jackson, R. J. & Hellen, C. U. T. ( 1998; ). A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs. Genes Dev 12, 67–83.[CrossRef]
    [Google Scholar]
  84. Pietschmann, T., Lohmann, V., Kaul, A., Krieger, N., Rinck, G., Rutter, G., Strand, D. & Bartenschlager, R. ( 2002; ). Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J Virol 76, 4008–4021.[CrossRef]
    [Google Scholar]
  85. Player, M. R. & Torrence, P. F. ( 1998; ). The 2–5A system: modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol Ther 78, 55–113.[CrossRef]
    [Google Scholar]
  86. Polyak, S. J., Khabar, K. S. A., Paschal, D. M., Ezelle, H. J., Duverlie, G., Barber, G. N., Levy, D. E., Mukaida, N. & Gretch, D. R. ( 2001; ). Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 75, 6095–6106.[CrossRef]
    [Google Scholar]
  87. Power, J. P., Lawlor, E., Davidson, F., Yap, P. L., Kenny-Walsh, E., Whelton, M. J. & Walsh, T. J. ( 1994; ). Hepatitis C viraemia in recipients of Irish intravenous anti-D immunoglobulin. Lancet 344, 1166–1167.
    [Google Scholar]
  88. Pradat, P. & Trepo, C. ( 2000; ). HCV: epidemiology, modes of transmission and prevention of spread. Baillières Best Pract Res Clin Gastroenterol 14, 201–210.[CrossRef]
    [Google Scholar]
  89. Pybus, O. G., Charleston, M. A., Gupta, S., Rambaut, A., Holmes, E. C. & Harvey, P. H. ( 2001; ). The epidemic behavior of the hepatitis C virus. Science 292, 2323–2325.[CrossRef]
    [Google Scholar]
  90. Pybus, O. G., Drummond, A. J., Nakano, T., Robertson, B. H. & Rambaut, A. ( 2003; ). The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach. Mol Biol Evol 20, 381–387.[CrossRef]
    [Google Scholar]
  91. Quer, J., Murillo, P., Martell, M., Gómez, J., Esteban, J. I., Esteban, R. & Guardia, J. ( 2004; ). Subtype mutations in the envelope 2 region including phosphorylation homology domain of hepatitis C virus do not predict effectiveness of antiviral therapy. J Viral Hepat 11, 45–54.[CrossRef]
    [Google Scholar]
  92. Ray, S. C., Arthur, R. R., Carella, A., Bukh, J. & Thomas, D. L. ( 2000; ). Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 182, 698–707.[CrossRef]
    [Google Scholar]
  93. Reiser, M. ( 2004; ). Antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, non-genotype 1. In Program and Abstracts of the 54th Annual Meeting of the American Association for the Study of Liver Diseases, 24–28 October 2003, Boston, MA, USA.
  94. Resti, M., Jara, P., Hierro, L., Azzari, C., Giacchino, R., Zuin, G., Zancan, L., Pedditzi, S. & Bortolotti, F. ( 2003; ). Clinical features and progression of perinatally acquired hepatitis C virus infection. J Med Virol 70, 373–377.[CrossRef]
    [Google Scholar]
  95. Reyes, G. R. ( 2002; ). The nonstructural NS5A protein of hepatitis C virus: an expanding, multifunctional role in enhancing hepatitis C virus pathogenesis. J Biomed Sci 9, 187–197.[CrossRef]
    [Google Scholar]
  96. Rodríguez-López, M., Riezu-Boj, J. I., Ruiz, M., Berasain, C., Civeira, M. P., Prieto, J. & Borrás-Cuesta, F. ( 1999; ). Immunogenicity of variable regions of hepatitis C virus proteins: selection and modification of peptide epitopes to assess hepatitis C virus genotypes by ELISA. J Gen Virol 80, 727–738.
    [Google Scholar]
  97. Rubbia-Brandt, L., Quadri, R., Abid, K. & 8 other authors ( 2000; ). Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 33, 106–115.[CrossRef]
    [Google Scholar]
  98. Ruggieri, A., Argentini, C., Kouruma, F., Chionne, P., D'Ugo, E., Spada, E., Dettori, S., Sabbatani, S. & Rapicetta, M. ( 1996; ). Heterogeneity of hepatitis C virus genotype 2 variants in West Central Africa (Guinea Conakry). J Gen Virol 77, 2073–2076.[CrossRef]
    [Google Scholar]
  99. Saito, T., Ito, T., Ishiko, H., Yonaha, M., Morikawa, K., Miyokawa, A. & Mitamura, K. ( 2003; ). Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b. Am J Gastroenterol 98, 1377–1383.[CrossRef]
    [Google Scholar]
  100. Santti, J., Hyypiä, T., Kinnunen, L. & Salminen, M. ( 1999; ). Evidence of recombination among enteroviruses. J Virol 73, 8741–8749.
    [Google Scholar]
  101. Sarisky, R. T. ( 2004; ). Non-nucleoside inhibitors of the HCV polymerase. J Antimicrob Chemother 54, 14–16.[CrossRef]
    [Google Scholar]
  102. Sarrazin, C., Herrmann, E., Bruch, K. & Zeuzem, S. ( 2002; ). Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J Virol 76, 11079–11090.[CrossRef]
    [Google Scholar]
  103. Saunders, L. R. & Barber, G. N. ( 2003; ). The dsRNA binding protein family: critical roles, diverse cellular functions. FASEB J 17, 961–983.[CrossRef]
    [Google Scholar]
  104. Seeff, L. B. ( 2002; ). Natural history of chronic hepatitis C. Hepatology 36, S35–S46.[CrossRef]
    [Google Scholar]
  105. Seeff, L. B., Hollinger, F. B., Alter, H. J. & 21 other authors ( 2001; ). Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 33, 455–463.[CrossRef]
    [Google Scholar]
  106. Serfaty, L., Andreani, T., Giral, P., Carbonell, N., Chazouillères, O. & Poupon, R. ( 2001; ). Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 34, 428–434.[CrossRef]
    [Google Scholar]
  107. Sheridan, I., Pybus, O. G., Holmes, E. C. & Klenerman, P. ( 2004; ). High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J Virol 78, 3447–3454.[CrossRef]
    [Google Scholar]
  108. Simmonds, P. ( 2001; ). The origin and evolution of hepatitis viruses in humans. J Gen Virol 82, 693–712.
    [Google Scholar]
  109. Simmonds, P. & Smith, D. B. ( 1999; ). Structural constraints on RNA virus evolution. J Virol 73, 5787–5794.
    [Google Scholar]
  110. Simmonds, P., Holmes, E. C., Cha, T.-A. & 7 other authors ( 1993; ). Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 74, 2391–2399.[CrossRef]
    [Google Scholar]
  111. Simmonds, P., Tuplin, A. & Evans, D. J. ( 2004; ). Detection of genome-scale ordered RNA structure (GORS) in genomes of positive-stranded RNA viruses: implications for virus evolution and host persistence. RNA 10, 1337–1351.[CrossRef]
    [Google Scholar]
  112. Simons, J. N., Pilot-Matias, T. J., Leary, T. P. & 9 other authors ( 1995; ). Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc Natl Acad Sci U S A 92, 3401–3405.[CrossRef]
    [Google Scholar]
  113. Smith, D. B., Pathirana, S., Davidson, F., Lawlor, E., Power, J., Yap, P. L. & Simmonds, P. ( 1997; ). The origin of hepatitis C virus genotypes. J Gen Virol 78, 321–328.
    [Google Scholar]
  114. Stuyver, L., Rossau, R., Wyseur, A., Duhamel, M., Vanderborght, B., Van Heuverswyn, H. & Maertens, G. ( 1993; ). Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 74, 1093–1102.[CrossRef]
    [Google Scholar]
  115. Takaki, A., Wiese, M., Maertens, G., Depla, E., Seifert, U., Liebetrau, A., Miller, J. L., Manns, M. P. & Rehermann, B. ( 2000; ). Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6, 578–582.[CrossRef]
    [Google Scholar]
  116. Tan, S.-L. & Katze, M. G. ( 2001; ). How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology 284, 1–12.[CrossRef]
    [Google Scholar]
  117. Tan, S.-L., Nakao, H., He, Y., Vijaysri, S., Neddermann, P., Jacobs, B. L., Mayer, B. J. & Katze, M. G. ( 1999; ). NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci U S A 96, 5533–5538.[CrossRef]
    [Google Scholar]
  118. Taniguchi, S., Okamoto, H., Sakamoto, M. & 7 other authors ( 1993; ). A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus E2/NS1 protein: implication for an escape from antibody. Virology 195, 297–301.[CrossRef]
    [Google Scholar]
  119. Taylor, D. R., Shi, S. T., Romano, P. R., Barber, G. N. & Lai, M. M. C. ( 1999; ). Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285, 107–110.[CrossRef]
    [Google Scholar]
  120. Thibeault, D., Bousquet, C., Gingras, R., Lagacé, L., Maurice, R., White, P. W. & Lamarre, D. ( 2004; ). Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J Virol 78, 7352–7359.[CrossRef]
    [Google Scholar]
  121. Thimme, R., Oldach, D., Chang, K. M., Steiger, C., Ray, S. C. & Chisari, F. V. ( 2001; ). Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194, 1395–1406.[CrossRef]
    [Google Scholar]
  122. Thomas, D. L. ( 2000; ). Hepatitis C epidemiology. Curr Top Microbiol Immunol 242, 25–41.
    [Google Scholar]
  123. Tokita, H., Okamoto, H., Tsuda, F. & 7 other authors ( 1994a; ). Hepatitis C virus variants from Vietnam are classifiable into the seventh, eighth, and ninth major genetic groups. Proc Natl Acad Sci U S A 91, 11022–11026.[CrossRef]
    [Google Scholar]
  124. Tokita, H., Shrestha, S. M., Okamoto, H., Sakamoto, M., Hirokita, M., Iizuka, H., Shrestha, S., Miyakawa, Y. & Mayumi, M. ( 1994b; ). Hepatitis C virus variants from Nepal with novel genotypes and their classification into the third major group. J Gen Virol 75, 931–936.[CrossRef]
    [Google Scholar]
  125. Tokita, H., Okamoto, H., Luengrojanakul, P., Vareesangthip, K., Chainuvati, T., Iizuka, H., Tsuda, F., Miyakawa, Y. & Mayumi, M. ( 1995; ). Hepatitis C virus variants from Thailand classifiable into five novel genotypes in the sixth (6b), seventh (7c, 7d) and ninth (9b, 9c) major genetic groups. J Gen Virol 76, 2329–2335.[CrossRef]
    [Google Scholar]
  126. Trozzi, C., Bartholomew, L., Ceccacci, A. & 10 other authors ( 2003; ). In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 77, 3669–3679.[CrossRef]
    [Google Scholar]
  127. Tuplin, A., Wood, J., Evans, D. J., Patel, A. H. & Simmonds, P. ( 2002; ). Thermodynamic and phylogenetic prediction of RNA secondary structures in the coding region of hepatitis C virus. RNA 8, 824–841.[CrossRef]
    [Google Scholar]
  128. Tuplin, A., Evans, D. J. & Simmonds, P. ( 2004; ). Detailed mapping of RNA secondary structures in core and NS5B-encoding region sequences of hepatitis C virus by RNase cleavage and novel bioinformatic prediction methods. J Gen Virol 85, 3037–3047.[CrossRef]
    [Google Scholar]
  129. Varaklioti, A., Vassilaki, N., Georgopoulou, U. & Mavromara, P. ( 2002; ). Alternate translation occurs within the core coding region of the hepatitis C viral genome. J Biol Chem 277, 17713–17721.[CrossRef]
    [Google Scholar]
  130. Walewski, J. L., Keller, T. R., Stump, D. D. & Branch, A. D. ( 2001; ). Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA 7, 710–721.[CrossRef]
    [Google Scholar]
  131. Wang, C., Pflugheber, J., Sumpter, R., Jr, Sodora, D. L., Hui, D., Sen, G. C. & Gale, M., Jr ( 2003; ). Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol 77, 3898–3912.[CrossRef]
    [Google Scholar]
  132. Wansbrough-Jones, M. H., Frimpong, E., Cant, B., Harris, K., Evans, M. R. W. & Teo, C. G. ( 1998; ). Prevalence and genotype of hepatitis C virus infection in pregnant women and blood donors in Ghana. Trans R Soc Trop Med Hyg 92, 496–499.[CrossRef]
    [Google Scholar]
  133. Wasley, A. & Alter, M. J. ( 2000; ). Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20, 1–16.[CrossRef]
    [Google Scholar]
  134. Watanabe, H., Nagayama, K., Enomoto, N., Itakura, J., Tanabe, Y., Hamano, K., Izumi, N., Sato, C. & Watanabe, M. ( 2003a; ). Sequence elements correlating with circulating viral load in genotype 1b hepatitis C virus infection. Virology 311, 376–383.[CrossRef]
    [Google Scholar]
  135. Watanabe, H., Nagayama, K., Enomoto, N., Itakura, J., Tanabe, Y., Sato, C., Izumi, N. & Watanabe, M. ( 2003b; ). Amino acid substitutions in PKR-eIF2 phosphorylation homology domain (PePHD) of hepatitis C virus E2 protein in genotype 2a/2b and 1b in Japan and interferon efficacy. Hepatol Res 26, 268–274.[CrossRef]
    [Google Scholar]
  136. Waterhouse, P. M., Wang, M.-B. & Lough, T. ( 2001; ). Gene silencing as an adaptive defence against viruses. Nature 411, 834–842.[CrossRef]
    [Google Scholar]
  137. Weiner, A. J., Geysen, H. M., Christopherson, C. & 12 other authors ( 1992; ). Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A 89, 3468–3472.[CrossRef]
    [Google Scholar]
  138. Witherell, G. W. & Beineke, P. ( 2001; ). Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response. J Med Virol 63, 8–16.[CrossRef]
    [Google Scholar]
  139. Xu, L.-Z., Larzul, D., Delaporte, E., Bréchot, C. & Kremsdorf, D. ( 1994; ). Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). J Gen Virol 75, 2393–2398.[CrossRef]
    [Google Scholar]
  140. Xu, Z., Choi, J., Yen, T. S. B., Lu, W., Strohecker, A., Govindarajan, S., Chien, D., Selby, M. J. & Ou, J. ( 2001; ). Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. EMBO J 20, 3840–3848.[CrossRef]
    [Google Scholar]
  141. Yee, T. T., Griffioen, A., Sabin, C. A., Dusheiko, G. & Lee, C. A. ( 2000; ). The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 47, 845–851.[CrossRef]
    [Google Scholar]
  142. You, S., Stump, D. D., Branch, A. D. & Rice, C. M. ( 2004; ). A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication. J Virol 78, 1352–1366.[CrossRef]
    [Google Scholar]
  143. Zeuzem, S. ( 2004; ). Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 140, 370–381.
    [Google Scholar]
  144. Zhang, Z.-X., Chen, M., Sönnerborg, A. & Sällberg, M. ( 1994; ). Antigenic structure of the complete nonstructural (NS) 2 and 5 proteins of hepatitis C virus (HCV): anti-HCV NS2 and NS5 antibody reactivities in relation to HCV serotype, presence of HCV RNA, and acute HCV infection. Clin Diagn Lab Immunol 1, 290–294.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80401-0
Loading
/content/journal/jgv/10.1099/vir.0.80401-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error